Edgewise Therapeutics, Inc.
EWTX
Clasificación en acciones
#3981
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Precio por acción
$38.12
Última sincronización: 2026-10-19
Capitalización bursátil
$4.10B
Cambio (1 día)
2.50%
Cambio (1 año)
147.69%
País
US
Comercio Edgewise Therapeutics, Inc. (EWTX)
Categoría
Healthcare
Ganancias de Edgewise Therapeutics, Inc. (EWTX)
Ganancias en Jun 2026 TTM: $-197.22M
Secondo gli ultimi rapporti finanziari di Edgewise Therapeutics, Inc., gli utili attuali della società sono $-197.22M. Nel 2023, la società ha registrato un utile di $-100.16M, una disminución en comparación con agli utili del 2022, che erano di $-67.64M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Edgewise Therapeutics, Inc. desde 2019 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-197.22M | 47.39% |
| 2024 | $-133.81M | 33.60% |
| 2023 | $-100.16M | 48.08% |
| 2022 | $-67.64M | 57.99% |
| 2021 | $-42.81M | 150.03% |
| 2020 | $-17.12M | 76.43% |
| 2019 | $-9.71M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -2,774.60% |
US
|
|
| $-3.09B | 1,465.24% |
US
|
|
| $-4.02B | 1,936.38% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,089.06% |
NL
|
